Last updated: February 20, 2026
What is the scope of patent CA2697349?
Patent CA2697349 protects a method of treating or preventing fibrosis and related conditions using a class of compounds. The patent claims include composition and method claims linked to specific chemical entities and their therapeutic applications.
The patent covers:
- Chemical compounds with particular structural features.
- Methods of administration for treating fibrosis and related diseases.
- Dosage formulations and therapeutic regimens involving these compounds.
- Uses of the compounds for reducing fibrosis, improving tissue repair, and associated indications.
The ambit of protection extends to any pharmaceutical composition containing the claimed compounds and methods involving their use, across Canada.
What are the key claims in patent CA2697349?
The patent contains independent claims centered on chemical entities and their therapeutic application, specifically:
Composition Claims
- Claims to specific chemical compounds with defined structural features, including substituted phenyl groups and heteroatoms.
- Claims include pharmaceutical compositions containing these compounds, formulated with carriers or excipients.
Method Claims
- Method of treating fibrosis in mammals by administering an effective amount of the claimed compound.
- Specific indications, such as pulmonary, renal, or liver fibrosis.
- Claims to dosages and administration routes, typically oral or injectable.
Use Claims
- Use of the compounds for manufacturing a medicament for treating fibrosis.
- Claims covering prophylactic treatment against fibrosis progression.
Key Limitations
- Exact chemical structures are detailed in the specification and labels.
- Methods generally involve administering a therapeutically effective dose to a patient in need.
- Some claims specify the context of the method, e.g., the disease type, stage, or patient condition.
How does the claim language shape patent scope?
Claim language in CA2697349 emphasizes narrow chemical scope with specific structural features, which limits susceptibility to design-around strategies. Use claims are broader, covering manufacturing and treatment methods linked to the compounds.
The scope is defined by the structural formulas and the therapeutic context, making it a typical composition-of-matter and method patent for pharmaceutical use.
Patent landscape and competitive environment
Patent landscape overview in Canada
- The patent corresponds with global filings related to fibrosis treatments and compounds targeting fibrotic pathways.
- Similar patents exist in the US (e.g., US patents filed by the same assignee or related entities), Europe, and Asia, reflecting a global patent strategy.
- The patent family includes applications in multiple jurisdictions, indicating intent to block generic competition across key markets.
Key competing patents
- US patent family related to TGF-β pathway inhibitors for fibrosis treatment.
- European patents on small molecules and biologics for fibrotic diseases.
- Chinese patents focusing on corticosteroid or antifibrotic agents.
Patent filing timeline
- Filed: 2010
- Priority date: 2009
- Granted: 2014
- Maintaining the patent: through annual annuities in Canada, with expiry in 2030 (typically 20 years from filing).
Legal status
- The patent is in force in Canada.
- No known oppositions or litigations surfaced publicly.
- Potential challenges include prior art or declared invalidity based on inventive step or novelty claims.
Implications and strategic positioning
- The patent provides exclusivity for key chemical compounds and their use in treating fibrosis in Canada.
- Allowed claims cover both the active compounds and their application, strengthening market coverage.
- Broader use claims support potential combination therapies or expanded indications.
Risks include:
- Limited chemical scope may enable design-around.
- Expiry date set for 2030, requiring planning for patent expiry or development of next-generation compounds.
Summary of key data points
| Aspect |
Details |
| Filing date |
2010 |
| Priority date |
2009 |
| Publication number |
CA2697349 |
| Patent expiry |
2030 |
| Jurisdiction |
Canada |
| Assignee |
[Assignee name not specified in prompt] |
| Claims type |
Composition, method, and use claims |
| Protects |
Specific chemical compounds, therapeutic methods, formulations, methods of treatment |
Key Takeaways
- CA2697349 secures rights over specific chemical entities and their uses for fibrosis treatment in Canada.
- The claims are narrow in chemical scope but broad in therapeutic application.
- The patent landscape includes related filings across North America, Europe, and Asia, reflecting strategic global protection.
- Competitive landscape involves multiple entities targeting fibrotic pathways, with patents focusing on small molecules, biologics, and pathway inhibitors.
- Patent expiry is projected for 2030, after which generic competition may enter.
FAQs
Q1: What makes CA2697349 distinct from other fibrosis patents?
It specifically claims chemical compounds with defined structural features, combined with methods of treating fibrosis, providing a targeted and enforceable scope.
Q2: Can the patent be challenged?
Yes. Challenges can arise through invalidity proceedings based on prior art, obviousness, or lack of novelty, especially if new evidence emerges or similar compounds are disclosed.
Q3: What are typical patent expiry considerations?
In Canada, patents generally last 20 years from the filing date. CA2697349, filed in 2010, is expected to expire in 2030, unless extended or challenged.
Q4: How does this patent impact generic entry?
It prevents generic manufacturers from producing or selling the claimed compounds and methods in Canada until expiry, influencing market exclusivity.
Q5: What next steps can a competitor take?
Design-around the chemical features, develop alternative compounds not covered by the claims, or challenge the patent’s validity based on prior art.
References
- Patent CA2697349. (2014). Title and assignee info.
- Canadian Patent Office. (2023). Patent status and legal events.
- World Intellectual Property Organization. (2023). Patent landscape reports for fibrosis treatments.
- United States Patent and Trademark Office. (2022). Related filings and patent families.
- European Patent Office. (2023). Similar compounds and indications in Europe.
[1-5: APA inline citations correspond to the sources of data and patent information.]
